Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

A Pharmacological Screening Approach for Discovery of Neuroprotective Compounds in Ischemic Stroke

  • Simret Beraki,

    Affiliation Behavioral and Functional Neuroscience Laboratory, Institute for Neuro-Innovation and Translational Neurosciences, School of Medicine, Stanford, California, United States of America

  • Lily Litrus,

    Affiliation BioSeek division of DiscoverX, South San Francisco, California, United States of America

  • Liza Soriano,

    Affiliation Pacific BioDevelopment Limited Liability Company, Emeryville, California, United States of America

  • Marie Monbureau,

    Affiliation Behavioral and Functional Neuroscience Laboratory, Institute for Neuro-Innovation and Translational Neurosciences, School of Medicine, Stanford, California, United States of America

  • Lillian K. To,

    Affiliation Behavioral and Functional Neuroscience Laboratory, Institute for Neuro-Innovation and Translational Neurosciences, School of Medicine, Stanford, California, United States of America

  • Steven P. Braithwaite,

    Affiliation Circuit Therapeutics, Menlo Park, California, United States of America

  • Karoly Nikolich,

    Affiliation Circuit Therapeutics, Menlo Park, California, United States of America

  • Roman Urfer,

    Affiliation Selonterra Limited Liability Company, Belmont, California, United States of America

  • Donna Oksenberg,

    Affiliation Global Blood Therapeutics, South San Francisco, California, United States of America

  • Mehrdad Shamloo

    mshamloo@stanford.edu

    Affiliation Behavioral and Functional Neuroscience Laboratory, Institute for Neuro-Innovation and Translational Neurosciences, School of Medicine, Stanford, California, United States of America

A Pharmacological Screening Approach for Discovery of Neuroprotective Compounds in Ischemic Stroke

  • Simret Beraki, 
  • Lily Litrus, 
  • Liza Soriano, 
  • Marie Monbureau, 
  • Lillian K. To, 
  • Steven P. Braithwaite, 
  • Karoly Nikolich, 
  • Roman Urfer, 
  • Donna Oksenberg, 
  • Mehrdad Shamloo
PLOS
x

Abstract

With the availability and ease of small molecule production and design continuing to improve, robust, high-throughput methods for screening are increasingly necessary to find pharmacologically relevant compounds amongst the masses of potential candidates. Here, we demonstrate that a primary oxygen glucose deprivation assay in primary cortical neurons followed by secondary assays (i.e. post-treatment protocol in organotypic hippocampal slice cultures and cortical neurons) can be used as a robust screen to identify neuroprotective compounds with potential therapeutic efficacy. In our screen about 50% of the compounds in a library of pharmacologically active compounds displayed some degree of neuroprotective activity if tested in a pre-treatment toxicity assay but just a few of these compounds, including Carbenoxolone, remained active when tested in a post-treatment protocol. When further examined, Carbenoxolone also led to a significant reduction in infarction size and neuronal damage in the ischemic penumbra when administered six hours post middle cerebral artery occlusion in rats. Pharmacological testing of Carbenoxolone-related compounds, acting by inhibition of 11-β-hydroxysteroid dehydrogenase-1 (11β-HSD1), gave rise to similarly potent in vivo neuroprotection. This indicates that the increase of intracellular glucocorticoid levels mediated by 11β-HSD1 may be involved in the mechanism that exacerbates ischemic neuronal cell death, and inhibiting this enzyme could have potential therapeutic value for neuroprotective therapies in ischemic stroke and other neurodegenerative disorders associated with neuronal injury.

Introduction

Stroke is the fourth leading cause of adult disability in the United States and a significant public health problem worldwide [1]. Neuroprotective therapies that can be administered after stroke to reduce further neuronal loss are, therefore, a critical area for research and drug development. Tissue plasminogen activator (tPA), currently the only approved therapy, must be administered within 3 hours of stroke onset and carries a risk of inducing cerebral hemorrhage (see review [2], [3]). Novel mechanisms and pharmacological agents are needed to treat patients who suffer a stroke in order to limit neuronal damage and improve clinical outcome. Here we report an approach to screen a library of pharmacologically active compounds in an in vitro model for ischemic injury using primary cortical neurons and hippocampal slices.

Understanding of the mechanisms underlying neuronal death has led to the proposal that several parallel cellular processes including excitotoxicity, ionic imbalance, oxidative stress, and apoptotic–like cell death contribute to delayed ischemic neuronal damage (see review [4], [5]). Despite numerous large clinical trials with compounds targeting these pathways at the individual level, none of these experimental treatments have been successful in generating lead therapeutics for ischemic stroke. This may further suggest that ischemic brain injury following stroke is mediated by activation of several of these complex signaling pathways, and targeting a selective signaling cascade would not be beneficial in protecting the tissue in this disorder. Therefore, approaches that can further define the mechanisms and relevance of pharmacological intervention are necessary to identify compounds of potential benefit.

In this study we used the oxygen glucose deprivation (OGD) model of ischemic neuronal death to identify neuroprotective compounds from a small library. With this approach, we identified Carbenoxolone, a compound known as a gap junction blocker (see review [6]) and modulator of 11-β-hydroxysteroid dehydrogenases [7], [8], as a neuroprotectant. This compound proved to be efficacious in an in vivo model of stroke and further delineation of its mechanism of action identified that inhibition of 11-β-hydroxysteroid dehydrogenase-1 (11β-HSD1) underlies, at least in part, its neuroprotective properties. The role of 11β-HSD1 is to modulate local levels of corticosteroids (reviewed in [9], [10]), acting as an oxoreductase to increase active glucocorticoid levels. Carbenoxolone’s neuroprotective properties were demonstrated in cultured hippocampal neurons [11], and 11β-HSD1 knockout mice are protected from age related decline in hippocampal function [12]. In addition, Carbenoxolone is neuroprotective when centrally [13] or peripherally [14] administered prior to ischemic injury.

The aim of this study was to discover development candidates by identifying neuroprotective compounds in primary cortical neurons and then confirm their activities in rodent models of stroke. After the initial screen, we focused our profiling on Carbenoxolone. Future efforts will extend our findings in further validating the importance of 11β-HSD1 in neuroprotection and prevention of functional loss in ischemic brain injury.

Materials and Methods

Ethics Statement

All experiments were in accordance with protocols approved by AGY’s Animal Care and Use Committee and were performed based on the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Sufficient actions were considered for reducing pain or discomfort of subjects during the experiments.

Animals and Reagents

All experimental procedures were approved by AGY’s Animal Care and Use Committee. Animal handling was performed in accordance with guidelines of National Institute of Health. Male Wistar rats were supplied by Harlan Laboratories (Harlan Inc., CA) at a body weight of 300–330 grams and approximately 9–10 weeks of age. The Library of Pharmacologically Active Compounds was purchased from Prestwick Chemical (The Prestwick Chemical Library, Illkirch, France) and all other chemicals were purchased from SigmaAldrich. BVT-2733 (3-chloro-2-methyl-N-(4-(2-(4-methylpiperazin-1-yl)-2-oxoethyl) thiazol-2-yl) benzenesulfonamide hydrochloride) was synthesized by a contract research organization.

Hippocampal Slice Cultures and Primary Cortical Neuronal Cultures

Rat hippocampal cultures were generated using techniques for culturing brain slices originally described in Stoppini et al [15] with modifications in Cronberg et al [16]. Briefly, the hippocampi of male rats were dissected and immersed in ice-cold HBSS, cut into 250-µm-thick sections using a tissue chopper and plated, one slice per insert, onto Millicell culture inserts (0.4 µm Millicell-CM, 12 mm in diameter, Millipore Corp., Bedford, MA). Cultures were maintained in a humidified atmosphere at 35°C in a CO2 incubator (Thermo-Forma Scientific, Marietta, MA) for 3 weeks before experiments. The culture medium, with osmolarity 330 mosM, consisted of 50% MEM (Eagles with Earl’s balanced salt solution), 25% heat inactivated horse serum, 18% HBSS and 2% B27 and was supplemented with 4 mM l-glutamine and 50 units of penicillin–streptomycin/ml. d-glucose was added to a final concentration of 20 mM. B27 was omitted after the first week of culture. All substances were from Invitrogen, Carlsbad, CA, with the exception of d-glucose, which was from Sigma, St. Louis, MO. Rat primary cortical neurons were prepared from E17 embryos. The brain cortices were dissected and the neurons dissociated, digested, and plated as previously described [17], [18]. Three days later, 5-fluoro-2′-deoxyuridine (30µM) was added. Cells were maintained for 12–14 days in Neurobasal medium (Gibco) supplemented with B27 (Gibco) and 2 mM glutamine in a humidified atmosphere at 37°C with 5% CO2.

Oxygen Glucose Deprivation (OGD)

Primary neuronal cultures were subjected to oxygen glucose deprivation for 120 minutes at 37°C. The cultures were placed in an anaerobic chamber (Forma Scientific) and incubated with a balanced salt solution (116 mM NaCl, 5.4 mM KCl, 1 mM NaH2PO4, 1.8 mm CaCl2, 26.2 mM NaHCO3, 0.01 mM glycine, pH = 7.4) lacking glucose and aerated with an anaerobic gas mix (85% N2/5%CO2/10% H2) to remove residual oxygen. Control cultures were kept in the original Neurobasal media and were submitted to the anaerobic conditions. At the end of the OGD insult, the cells were removed from the anaerobic chamber, the OGD media was replaced with Neurobasal media containing B27, and the cells were incubated for an additional 24 hours [16]. The compounds were present for 60 minutes prior to deprivation, during the 120 minute OGD, and for 24 hours post-OGD (pre-during-post) or only post hypoxic-hypoglycemic episode.

Propidium Iodide (PI) Staining

Cell death was measured with Propidium Iodide (PI) staining as described in Cronberg et al [16] with slight modification. PI (1 µg/mL) was added to the culture medium 24 hours before OGD insult. Images were captured pre-OGD and 24 hours post-OGD using a fluorescent microscope and camera. ImageJ software (National Institutes of Health, Bethesda, Maryland) was used to measure fluorescence intensity from the images, representing PI uptake. For each image, the mean fluorescence intensity (MFI) was recorded for six random square areas within the area of interest. One background MFI value was recorded from a random square area outside of the area of interest, in the upper left corner of the image slice. The six values were averaged and the MFI of the background staining was subtracted from this average and this result was reported as the final MFI for each image.

NMDA Toxicity

Primary neuronal cultures were exposed to 25 µM NMDA for 10 min at 37°C in a control salt solution (25 mM Tris, pH = 7.4, 120 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 15 mM D-glucose) containing 0.01 mM glycine [18], [19]. The exposure solution of the cells was then washed away and replaced by Neurobasal media containing B27 and the cells were placed in an incubator for 24 hours to recover. The test compounds were added to the neurons 2 hours prior to the NMDA addition and were also present during the NMDA insult and the recovery period or added only after the NMDA episode.

Cell Viability

Adenosine Triphosphate (ATP) content was measured as an index for cell viability using Celltiter Glo (Promega, Madison, WI) according to the manufacturer’s instructions. Cells were seeded at 10,000 cells per well in a 96-well plate. This was determined to be within the linear range of the Celltiter Glo assay via titration of 0 to 50,000 cells per well prior to experimentation based on the manufacturer guidelines.

Middle Cerebral Artery Occlusion

The transient middle cerebral artery occlusion (tMCAo) was performed in male Wistar rats according to Memezawa et al. [20] with some minor modifications. Briefly, a small incision was made in the common carotid artery and a nylon monofilament was inserted into the internal carotid artery through the common carotid artery. An occlusion time of 90 minutes was allowed in all rats subjected to tMCAo after which the filament was removed. The body temperature of rats subjected to tMCAo was maintained at 37±1°C for 6 hours after the occlusion.

Measurement of Infarct Volume

Rats were subjected to 90 minutes of tMCAo and were decapitated after 24 h of reperfusion for determination of infarction volume. The isolated brains were quickly placed in cold saline for 20 minutes, sliced in seven coronal slices (2 mm thick), and stained in a 1.0% 2,3,5- triphenyltetrazolium chloride (TTC) solution in saline at 37°C for 30 minutes [21]. The same procedures were performed for sham-operated animals. The stained brain tissues were fixed in 10% formalin in phosphate-buffered saline. The images were captured using a CCD camera (Panasonic Corporation, Japan) and the unstained damaged areas were defined as infarcted tissue and were quantified using Image Pro Plus 4.1 software (Media Cybernetics, Silver Spring, MD).

Data Analysis

All data analysis was performed using Graphpad Prism version 5 (Graphpad Software, San Diego, CA). The D’Agostino & Pearson omnibus normality test was utilized to determine Gaussian distribution. All normally distributed values are presented in the text as mean ± Standard Error of Mean (SEM) while non-Gaussian distributed values are reported as median (range). Values of p<0.05 were considered statistically significant. Testing for significant differences between two groups was performed using an unpaired Student’s t-test for values with Gaussian distribution and a Mann-Whitney U-test for values without Gaussian distribution. Differences between three or more treatment groups were analyzed using one-way Analysis of Variance (ANOVA) for Gaussian distributions and the Kruskal-Wallis test for values without Gaussian distribution. For post-hoc analysis, either the Dunnett’s Multiple Comparison Test or the Dunn’s Multiple Comparison Test was done when appropriate. Statistical tests used for each data set are indicated in the figure legends.

Results

We screened a library of pharmacologically active compounds using oxygen-glucose deprivation assays (OGD) with primary cortical neurons to identify potentially neuroprotective compounds for cerebral ischemia. In this initial screen of compounds at a concentration of 10µM, with the compound present pre-, during, and post-OGD (PDP), a remarkable 50% of the 880 screened compounds showed neuroprotection at a level of 50% of the positive control (Figure 1a). The complete list of the compounds tested and their level of neuroprotection is presented in the Table S1. Neuroprotective compounds belonged to a diverse set of pharmacological classes including antibacterial, anti-inflammatory, anti-coagulant, and antihyperlipidemic compounds (Figure 1b). We then selected 21 representative compounds from these classes (Figure 1b) and tested their neuroprotective activity in the OGD model when applied either PDP or only post OGD (Table 1). The majority of these compounds were neuroprotective when tested PDP while less than half displayed neuroprotective activity when tested post OGD (Table 1). We also tested these neuroprotective compounds in an NMDA-induced toxicity assay in which neuronal death is induced by 25µM NMDA. Sixty two percent of tested compounds showed neuroprotective activity with greater than 50% protection compared to the positive control when applied concurrently with NMDA and 45% of the tested compounds were neuroprotective when present only after the addition of NMDA to the cell cultures (Table 2). Out of these tested compounds, the following compounds displayed neuroprotective activity in all assays performed (PDP and Post treatment assays in both NMDA and OGD models): 1) Moxalactam disodium salt (Antibacterial), 2) Idoxuridine (Antiviral (anti-herpesvirus); Interacts with DNA, anticancer (glioma), radiation sensitizer), 3) Piperine (Antinematodal anti-inflammatory, hypotensive, chemopreventive, antioxidant, monoamine oxidase inhibitor), 4) Clofibric acid (Antilipidemic, cholesterol-lowering activity), 5) Meclofenoxate hydrochloride (Nootropic, Cholinergic agent), 6) Fipexide hydrochloride (Dopamine agonist, nootropic) 7) Catechin-(+,-) hydrate (Antioxidant, sulfated flavanoid pro-apoptotic, anti-proliferative, ameliorates cognitive impairement and neurodegeneration in an AD animal model).

thumbnail
Figure 1. Neuroprotection and class of screened compounds.

A library of pharmacologically active compounds was screened using an oxygen-glucose deprivation (OGD) assay with primary cortical neurons to identify neuroprotective compounds (a). At 24 hours post-OGD, approximately 50% of the 880 screened compounds showed neuroprotection at levels over 50% compared to controls (a). Compounds that showed protection represent an array of pharmacological classes including antibacterial, anti-inflammatory, anti-coagulant, and anti-hyperlipidemic compounds (b). The complete list of compounds tested and the degree of protection is displayed in Table S1.

http://dx.doi.org/10.1371/journal.pone.0069233.g001

thumbnail
Table 1. List of compounds displaying post-injury neuroprotective activity in the oxygen glucose deprivation (OGD) assay in cortical neurons.

http://dx.doi.org/10.1371/journal.pone.0069233.t001

thumbnail
Table 2. List of compounds displaying post-injury neuroprotective activity in the NMDA-induced toxicity assay in cortical neurons.

http://dx.doi.org/10.1371/journal.pone.0069233.t002

To confirm the neuroprotective activity of one of these compounds, Carbenoxolone, primary cortical neurons were subjected to 2 hours of OGD and neuronal damage was assayed using the Cell Titer Glo assay at 24 hours of recovery. Carbenoxolone (10µM) demonstrated significant neuroprotective activity in both PDP (p<0.001 vs. Vehicle) and post-OGD (p<0.05 vs. Vehicle) (Figure 2b). The hippocampus is particularly vulnerable to ischemic damage. Therefore, Carbenoxolone’s neuroprotective activity was tested in OGD of organotypic hippocampal slices. This assay extends the investigation of Carbenoxolone’s neuroprotective activity to a model with an intact neuronal network. Cell death was assayed by Propidium Iodide staining prior to and one day after OGD (Figure 3). Slices treated with vehicle displayed high neurotoxicity subsequent to OGD throughout the hippocampus (Figure 3a). Treatment with 10µM Carbenoxolone significantly protected against hippocampal cell death (p<0.01 vs. Vehicle, Figure 3b). The degree of neuroprotection was similar to that detected by the NMDA receptor antagonist MK801 (p<0.001 vs. Vehicle), a proven neuroprotective agent that inhibits the calcium flux via the NMDA receptor in pretreatment models (Figure 3b).

thumbnail
Figure 2. Molecular structure and neuroprotection of Carbenoxolone.

Molecular structure of Carbenoxolone, a synthetic derivative (succinyl ester) of Glycyrrhetinic acid (constituent of licorice). Carbenoxolone is an inhibitor of 11β steroid dehydrogenase enzymes (HSD1 and HSD2) and gap junctions (a). Protection against OGD-induced neuronal damage by Carbenoxolone. Primary cortical neurons were subjected to 2 hours of OGD and neuronal damage was assayed using the Cell Titer Glo assay at 24 hours of recovery, in presence of vehicle, 10 µM Carbenoxolone pre-during-post (PDP) (***p<0.001 vs. Vehicle; n = 10–13), or exclusively post OGD (Post) (*p<0.05 vs. Vehicle; n = 10–13). Carbenoxolone demonstrated neuroprotective activity in both PDP and post treatment experiments (n = 10–13) (b). Data were assessed via one-way ANOVA and significant results of the Dunnett’s post-test are shown with lines representing mean.

http://dx.doi.org/10.1371/journal.pone.0069233.g002

thumbnail
Figure 3. Carbenoxolone attenuates delayed OGD-induced hippocampal cell death.

Hippocampal slice cultures were exposed to oxygen-glucose deprivation (OGD) and stained with Propidium iodide (PI). Photographs of the control and OGD slices at pre- and 24 hours post-OGD. A representative image is shown for each experiment (n = 4). MK-801 (Dizocilpine) was used as a positive control (a). The compounds were added 2 hours prior to the OGD insult. Mean fluorescence intensity (MFI) was measured 24 hours post-OGD. Both 10 µM Carbenoxolone (n = 12) (**p<0.01) and 10 µM MK-801 (n = 12) (***p<0.001) significantly reduced cell death compared to the vehicle group (n = 12) (b). Data were assessed using the Kruskal-Wallis test and significant results from Dunn’s Multiple Comparison test are displayed. Box plots represent median and quartiles and whiskers show minimum and maximum values.

http://dx.doi.org/10.1371/journal.pone.0069233.g003

Transient middle cerebral artery occlusion (tMCAo) of rats was performed to assess the in vivo efficacy of Carbenoxolone in an animal model of stroke. To determine the most efficacious dose of carbenoxolone, the outcome after tMCAo was measured at doses of 10, 20, 30, 40, and 60 mg/kg (Figure 4). The treatment was administered at two timepoints with the first one given at 5 min pre-tMCAo and the second one at 3 hours post-tMCAo (Figure 4). Vehicle treated animals showed an infarct size of 225.2±13.5 mm3 (n = 19), measured 24 hours after the commencement of a 90 min tMCAo insult (Figure 4). Administration of Carbenoxolone at a total dose of 60 mg/kg (30 mg/kg 5 min prior to tMCAo; 30 mg/kg 3 hours post tMCAo) significantly reduced the brain infarct area (Figure 4, 90.3±28.4 mm3, p<0.05) compared to the vehicle group (Figure 4, 225.4±13.5 mm3) and compared to the 10 mg/kg treated group (Figure 4, 273.4 (237.4–323.4) mm3, p<0.01). The minimum significantly efficacious total dose was 40 mg/kg (20 mg/kg 5 min prior to tMCAo; 20 mg/kg 3 hours post tMCAo) with an infarct size of 91.8 (21.4–149.8) mm3 (Figure 4). In order to investigate the therapeutic window and whether Carbenoxolone retains its neuroprotective activity when treatment is initiated only after the neuronal injury, we administered Carbenoxolone at the same regimen (two doses of 30 mg/kg with a 3 hour interval for a total dose of 60 mg/kg) starting treatment at 1.5, 3, or 6 hours post-occlusion (Figure 5). This treatment regimen resulted in a reduction of the brain infarct area in 1.5 hours (108.5±21.1 mm3, p<0.001), 3 hours (89.3±17.2 mm3, p<0.001), and 6 hours (125.8±15.9 mm3, p<0.001) post treatment groups compared to vehicle (258.2±11.2 mm3) treated groups (Figure 5b).

thumbnail
Figure 4. Treatment with Carbenoxolone attenuates ischemic brain injury.

Animals were subjected to 90 minutes of tMCAo and were treated 5 minutes pre-tMCAo and 3 hours post-tMCAo with Carbenoxolone or vehicle (H2O) at the indicated total doses. Total infarction size was significantly decreased in tMCAo animals treated with 40 mg/kg (n = 5) (**p<0.01) and 60 mg/kg (n = 8) (**p<0.01) as compared to the 10 mg/kg treated group (n = 7) as well as in the 60 mg/kg (n = 8) (*p<0.05) group as compared to the vehicle group (n = 19). Data were assessed using the Kruskal-Wallis test and significant results from Dunn’s Multiple Comparison test are shown. Box plots represent median and quartiles and whiskers show minimum and maximum values.

http://dx.doi.org/10.1371/journal.pone.0069233.g004

thumbnail
Figure 5. Post treatment in vivo efficacy of Carbenoxolone.

Animals were subjected to 90 minutes of tMCAo treatment with 60 mg/kg total dose at 3 hours (30 mg/kg) and 6 hours (30 mg/kg) post-MCAo. Neuronal damage was quantified by TTC staining (n = 8–45), white (infarction), red (normal tissue) (a). Exploration of Carbenoxolone therapeutic window post-MCAo injury: Carbenonxolone was administered at a 60 mg/kg total dose (2×30 mg/kg) with a 3 hour interval with the first dose delivered at 1.5, 3, or 6 hours post-treatment (tx = treatment). The injuries in all the groups were quantified by TTC staining at 24 hours post injury (b). Data were assessed via one-way ANOVA and significant results of the Dunnett’s post-test and means are shown.

http://dx.doi.org/10.1371/journal.pone.0069233.g005

In an independent study, we further explored the longer term functional recovery post stroke in Carbenoxolone treated animals. We found that all the animals treated with this neuroprotective dose of Carbenoxolone died within 7 days post-treatment. This finding demonstrates that a novel chemical entity could provide acute neuroprotective activity but could lack long-term functional improvement because of general toxicity. To investigate and potentially dissociate the mechanisms of Carbenoxolone’s neuroprotection and toxicity, respectively, we tested the hypothesis that inhibition of 11β-HSD1 mediates neuroprotection while inhibition of the 11β-HSD2 leads to general toxicity. Therefore, we tested the 11β-HSD1 specific inhibitor BVT-2733 in the tMCAo model in rats (Figure 6a). Treatment with 60 mg/kg BVT-2733 in two doses of 30 mg/kg, administered 3 and 7 hours post-reperfusion, resulted in a significant reduction in brain infarct volume (Figure 6b and 6c, vehicle 131.7±11.3 mm3, BVT-2733 66.2±11.4 mm3, p<0.001) compared to vehicle. In vitro analysis and long-term functional recovery testing of this compound has not yet been conducted; therefore we cannot conclude whether 11β-HSD1 specific inhibitor BVT-2733 is indeed less toxic than Carbenoxolone.

thumbnail
Figure 6. Molecular structure and neuroprotection of BVT-2733.

Molecular structure of the specific 11β-HSD1 inhibitor, BVT-2733 (3-chloro-2-methyl-N-(4-(2-(4-methylpiperazin-1-yl)-2-oxoethyl) thiazol-2-yl) benzenesulfonamide hydrochloride) (a). Animals were subjected to 90 minutes of tMCAo and were treated with BVT-2733 30 mg/kg or vehicle (PEG 500 20%, DMSO 4%) at 3 hours and 7 hours post-reperfusion, for a total dosage of 60 mg/kg. Treatment with BVT-2733 (IP, intraperitoneal) (n = 10–11 in each treatment group) attenuated the ischemic brain injury (b). Data were assessed using an unpaired Student’s t-test. Scatter plots with mean values and significance is shown. Representative images of brain sections of treated animals: Neuronal damage was quantified by TTC staining; white indicates infarction and red staining indicates normal tissue (c).

http://dx.doi.org/10.1371/journal.pone.0069233.g006

Discussion

In the current study we screened a library of pharmacologically active compounds in order to identify novel therapeutic targets and compounds with neuroprotective activity. We identified 440 compounds with neuroprotective activity from over 12 therapeutic classes, including anti-inflammatory compounds and antibiotics. Our results showed that 50% of compounds screened in the pretreatment protocol displayed neuroprotective activity. We then made an educated selection of a subset of these compounds, and further confirmed compounds with a wide range of neuroprotective activity in both the NMDA toxicity assay as well as in OGD. Ten compounds (34%) showed neuroprotective activity in the post OGD assay and 13 compounds (45%) protected from NMDA excitotoxicity. We focused our efforts on Carbenoxolone, a synthetic derivative of Glycyrrhizinic acid, based on its described anti-inflammatory activity. Carbenoxolone was used clinically for treatment of oesophageal and ulcerative inflammation and has multiple biological effects that include the blocking of gap junctions [6], [22], [23] and non-specific inhibition of 11β-HSD enzymes [7]. Studies with cultured neurons have shown neuroprotection [24] and enhancement of NMDA induced cytotoxicity [25]. Additionally, Carbenoxolone was neuroprotective in vivo in a model of in utero hypoxia [26] and showed beneficial cognitive effects in clinical trials [27], [28]. However, the non-specific nature of Carbenoxolone’s mechanism led to clinical difficulties. In particular its inhibition of 11β-HSD2 was potentially responsible for hypertension and a syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol (for review see [9]; [29]). The low blood-brain-barrier permeability of the compound [30] would necessitate large doses (40–60 mg/kg), which could in turn lead to a greater potential for peripheral side effects. In the present study, animals administered Carbenoxolone did not survive past 7 days post-treatment and long-term evaluation of neurological deficit was not possible. Therefore, despite acute beneficial in vitro and in vivo effects, it is unlikely that Carbenoxolone would become a viable drug for ischemic brain injury.

We therefore sought to understand the specific mechanism by which Carbenoxolone exhibits neuroprotection. Blockade of gap junctions is a viable mechanism for limiting neuronal damage in stroke as the ischemic insult and subsequent reperfusion can lead to aberrant neuronal firing between cells [31]. However, cortical neurons cultured under conditions with glial cell inhibition and a serum free media are unlikely to have significant gap junctional coupling and Carbenoxolone’s in vitro activity is unlikely to function through this mechanism, which is consistent with other studies [32]. Nevertheless, traffic of potentially harmful cytosolic messengers between ischemic cells and surrounding non-ischemic cells might cause an increase of post-stroke injury [33]. It is possible that minimizing gap junction permeability via a gap junction blocker before occluding the middle cerebral artery might reduce the infarct volume. Therefore, the possibility that Carbenoxolone acts via gap junction blockade to decrease infarction volume cannot be eliminated.

The other major functional mechanism of Carbenoxolone is the inhibition of 11β-HSD enzymes [34], [35] and, within the brain, 11β-HSD1 is by far the most prevalent isozyme (see review [36]). Inhibition of 11β-HSD2 is detrimental and is known to cause cortisol-dependent activation of the mineralocorticoid receptor with sodium retention resulting in hypertension [37]. We therefore studied the specific inhibition of the 11β-HSD1 isoform using the 11β-HSD1 specific inhibitor, BVT-2733. Indeed, BVT-2733 was capable of reducing brain infarct volumes in the rat tMCAo model, suggesting that Carbenoxolone’s neuroprotective properties are, at least partially, a result of 11β-HSD1 inhibition. 11β-HSD1 has an oxo-reductase activity capable of converting glucocorticoids from inactive to active forms at local sites of action [11], [38], [39]. It is expressed at high levels in CNS neurons ([40], [41], [42] See review [43]), as are corticosteroid receptors [8], suggesting that glucocorticoid regulation within the brain is functionally important. Circulating glucocorticoid levels are determined by the hypothalamic-pituitary-adrenal (HPA) axis, and pathological abnormalities in this axis have been linked to the risk of stroke [44]. Glucocorticoids have numerous functions in the brain’s response to stress, including regulation of synaptic plasticity [45] and mediating inflammatory responses. In stroke, inflammation is a key mediator of secondary neuronal damage [46]. Glucocorticoids are widely used as anti-inflammatory agents in the periphery; however, mounting evidence suggests that they can have pro-inflammatory roles in the CNS (reviewed in [47]). Our studies indicate that the localized modulation of glucocorticoid levels by 11β-HSD1 may be important in the secondary damage occurring in stroke. Therapeutic intervention to modulate glucocorticoid levels may therefore provide a novel mechanism for treating stroke. Furthermore, the neuroprotective activity of antibiotics reported in this study and in the literature [48] could also be explained by similar mechanistic pathways, inhibition of neuroinflammation, which is a secondary effect of this class of compounds [49].

The next phase of research will focus on exploring the potential use of Carbenoxolone-related compounds with 11β-HSD1 inhibition activity for neuroprotection. In particular, long-term neurological deficit evaluation needs to be completed in tMCAo rats subject to treatment to ensure that the neuroprotective activity seen in this study is the result of preventing injury rather that delaying injury. The current study measures infract volumes at 24 hours post-reperfusion. In addition, the hypothesis that inhibition of 11β-HSD2 causes the toxicity of Carbenoxolone, and therefore an exclusive 11β-HSD1 inhibitor such as BVT-2733 should provide neuroprotective benefits without toxicity, needs to be further explored in terms of functional recovery and long term protection. Once completed, this additional work will provide a substantial improvement to our understanding of the mechanism of neuroprotective activity of 11β-HSD1 inhibitors.

Conclusions

We have demonstrated that OGD treatment in cortical neurons can be used as a primary screen to identify compounds with neuroprotective activity for ischemic stroke. Using this screening approach we have identified more than 400 compounds with neuroprotective activity in a pre-treatment protocol (Figure 7). However, just a few of these compounds displayed post-injury neuroprotective activity, which emphasizes the importance of applying post treatment protocols for screening and validation of neuroprotective compounds. We have shown that Carbenoxolone is a neuroprotective drug when given as late as 6 hours after the onset of the ischemic insult. However, the high doses used to achieve this neuroprotection can lead to toxicity. We showed that the neuroprotective activity of Carbenoxolone is mediated, at least in part, by inhibition of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Our findings suggest that the increase of intracellular glucocorticoid levels mediated by 11β-HSD1 post brain injury may be a mechanism that exacerbates ischemic neuronal cell death, and inhibiting this enzyme could be used as a potential approach to neuroprotective therapies in ischemic stroke and other neurodegenerative disorders.

thumbnail
Figure 7. Profiling flow-chart to identify neuroprotective compounds with potential therapeutic efficacy.

http://dx.doi.org/10.1371/journal.pone.0069233.g007

Supporting Information

Table S1.

Complete list of compounds tested and degree of neuroprotection. Neuroprotective compounds belonged to a diverse set of pharmacological classes including antibacterial, anti-inflammatory, anti-coagulant, and antihyperlipidemic compounds.

doi:10.1371/journal.pone.0069233.s001

(DOCX)

Author Contributions

Conceived and designed the experiments: MS. Performed the experiments: MS LL LS. Analyzed the data: MS LL LS SB MM LT. Wrote the paper: MS SB MM LT. Contributed intellectually to the work: SPB KN RU DO.

References

  1. 1. Towfighi A, Saver JL (2011) Stroke declines from third to fourth leading cause of death in the United States: historical perspective and challenges ahead. Stroke 42: 2351–2355. doi: 10.1161/strokeaha.111.621904
  2. 2. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP (2009) Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 40: 2945–2948. doi: 10.1161/strokeaha.109.192535
  3. 3. Finley Caulfield A, Wijman CA (2006) Critical care of acute ischemic stroke. Crit Care Clin 22: 581–606: abstract vii.
  4. 4. Lipton P (1999) Ischemic cell death in brain neurons. Physiol Rev 79: 1431–1568.
  5. 5. Tymianski M (2011) Emerging mechanisms of disrupted cellular signaling in brain ischemia. Nat Neurosci 14: 1369–1373. doi: 10.1038/nn.2951
  6. 6. Rozental R, Srinivas M, Spray DC (2001) How to close a gap junction channel. Efficacies and potencies of uncoupling agents. Methods Mol Biol 154: 447–476. doi: 10.1385/1-59259-043-8:447
  7. 7. Sewell KJ, Shirley DG, Michael AE, Thompson A, Norgate DP, et al. (1998) Inhibition of renal 11beta-hydroxysteroid dehydrogenase in vivo by carbenoxolone in the rat and its relationship to sodium excretion. Clin Sci (Lond) 95: 435–443. doi: 10.1042/cs19980157
  8. 8. Seckl JR, Kelly PA, Sharkey J (1991) Glycyrrhetinic acid, an inhibitor of 11 beta-hydroxysteroid dehydrogenase, alters local cerebral glucose utilization in vivo. J Steroid Biochem Mol Biol 39: 777–779. doi: 10.1016/0960-0760(91)90379-j
  9. 9. Stewart PM, Krozowski ZS (1999) 11 beta-Hydroxysteroid dehydrogenase. Vitam Horm 57: 249–324. doi: 10.1016/s0083-6729(08)60646-9
  10. 10. White PC, Mune T, Agarwal AK (1997) 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 18: 135–156. doi: 10.1210/edrv.18.1.0288
  11. 11. Rajan V, Edwards CR, Seckl JR (1996) 11 beta-Hydroxysteroid dehydrogenase in cultured hippocampal cells reactivates inert 11-dehydrocorticosterone, potentiating neurotoxicity. J Neurosci 16: 65–70.
  12. 12. Yau JL, Noble J, Kenyon CJ, Hibberd C, Kotelevtsev Y, et al. Lack of tissue glucocorticoid reactivation in 11beta -hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments. Proc Natl Acad Sci U S A 98: 4716–4721. doi: 10.1073/pnas.071562698
  13. 13. Khorasani MZ, Hosseinzadeh SA, Vakili A (2009) Effect of central microinjection of carbenoxolone in an experimental model of focal cerebral ischemia. Pak J Pharm Sci 22: 349–354.
  14. 14. Vakili A, Hosseinzadeh SA, Khorasani MZ (2009) Peripheral administration of carbenoxolone reduces ischemic reperfusion injury in transient model of cerebral ischemia. J Stroke Cerebrovasc Dis 18: 81–85. doi: 10.1016/j.jstrokecerebrovasdis.2008.09.018
  15. 15. Stoppini L, Buchs PA, Muller D (1991) A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 37: 173–182. doi: 10.1016/0165-0270(91)90128-m
  16. 16. Cronberg T, Rytter A, Asztély F, Söder A, Weiloch T (2004) Glucose but not lactate in combination with acidosis aggravates ischemic neuronal death in vitro. Stroke 35: 753–757. doi: 10.1161/01.str.0000117576.09512.32
  17. 17. Brewer GJ (1995) Serum-free B27/neurobasal medium supports differentiated growth of neurons from the striatum, substantia nigra, septum, cerebral cortex, cerebellum, and dentate gyrus. J Neurosci Res 42: 674–683. doi: 10.1002/jnr.490420510
  18. 18. Shamloo M, Soriano L, Wieloch T, Nikolich K, Urfer R, et al. (2005) Death-associated protein kinase is activated by dephosphorylation in response to cerebral ischemia. J Biol Chem 280: 42290–42299. doi: 10.1074/jbc.m505804200
  19. 19. Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH (1991) Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci U S A 88: 6368–6371. doi: 10.1073/pnas.88.14.6368
  20. 20. Memezawa H, Minamisawa H, Smith ML, Siesjo BK (1992) Ischemic penumbra in a model of reversible middle cerebral artery occlusion in the rat. Exp Brain Res 89: 67–78. doi: 10.1007/bf00229002
  21. 21. Benedek A, Moricz K, Juranyi Z, Gigler G, Levay G, et al. (2006) Use of TTC staining for the evaluation of tissue injury in the early phases of reperfusion after focal cerebral ischemia in rats. Brain Res 1116: 159–165. doi: 10.1016/j.brainres.2006.07.123
  22. 22. Frantseva MV, Kokarovtseva L, Naus CG, Carlen PL, MacFabe D, et al. Specific gap junctions enhance the neuronal vulnerability to brain traumatic injury. J Neurosci 22: 644–653.
  23. 23. Frantseva MV, Kokarovtseva L, Perez Velazquez JL (2002) Ischemia-induced brain damage depends on specific gap-junctional coupling. J Cereb Blood Flow Metab 22: 453–462. doi: 10.1097/00004647-200204000-00009
  24. 24. Naus CC, Ozog MA, Bechberger JF, Nakase T (2001) A neuroprotective role for gap junctions. Cell Commun Adhes 8: 325–328. doi: 10.3109/15419060109080747
  25. 25. Zundorf G, Kahlert S, Reiser G (2007) Gap-junction blocker carbenoxolone differentially enhances NMDA-induced cell death in hippocampal neurons and astrocytes in co-culture. J Neurochem 102: 508–521. doi: 10.1111/j.1471-4159.2007.04509.x
  26. 26. de Pina-Benabou MH, Szostak V, Kyrozis A, Rempe D, Uziel D, et al. (2005) Blockade of gap junctions in vivo provides neuroprotection after perinatal global ischemia. Stroke 36: 2232–2237. doi: 10.1161/01.str.0000182239.75969.d8
  27. 27. Sandeep TC, Walker BR (2001) Pathophysiology of modulation of local glucocorticoid levels by 11beta-hydroxysteroid dehydrogenases. Trends Endocrinol Metab 12: 446–453. doi: 10.1016/s1043-2760(01)00499-4
  28. 28. Sandeep TC, Yau JL, MacLullich AM, Noble J, Deary IJ, et al. (2004) 11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci U S A 101: 6734–6739. doi: 10.1073/pnas.0306996101
  29. 29. Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, et al. (1987) Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 2: 821–824. doi: 10.1016/s0140-6736(87)91014-2
  30. 30. Leshchenko Y, Likhodii S, Yue W, Burnham WM, Perez Velazquez JL (2006) Carbenoxolone does not cross the blood brain barrier: an HPLC study. BMC Neurosci 7: 3. doi: 10.1186/1471-2202-7-3
  31. 31. Rawanduzy A, Hansen A, Hansen TW, Nedergaard M (1997) Effective reduction of infarct volume by gap junction blockade in a rodent model of stroke. J Neurosurg 87: 916–920. doi: 10.3171/jns.1997.87.6.0916
  32. 32. Rouach N, Segal M, Koulakoff A, Giaume C, Avignone E (2003) Carbenoxolone blockade of neuronal network activity in culture is not mediated by an action on gap junctions. J Physiol 553: 729–745. doi: 10.1113/jphysiol.2003.053439
  33. 33. Perez Velazquez JL, Frantseva MV, Carlen PL (1997) In vitro ischemia promotes glutamate-mediated free radical generation and intracellular calcium accumulation in hippocampal pyramidal neurons. J Neurosci 17: 9085–9094.
  34. 34. Bonvalet JP, Doignon I, Blot-Chabaud M, Pradelles P, Farman N (1990) Distribution of 11 beta-hydroxysteroid dehydrogenase along the rabbit nephron. J Clin Invest 86: 832–837. doi: 10.1172/jci114781
  35. 35. Morita H, Zhou M, Foecking MF, Gomez-Sanchez EP, Cozza EN, et al. 11 beta-Hydroxysteroid dehydrogenase type 2 complementary deoxyribonucleic acid stably transfected into Chinese hamster ovary cells: specific inhibition by 11 alpha-hydroxyprogesterone. Endocrinology 137: 2308–2314. doi: 10.1210/endo.137.6.8641180
  36. 36. Holmes MC, Seckl JR (2006) The role of 11beta-hydroxysteroid dehydrogenases in the brain. Mol Cell Endocrinol 248: 9–14. doi: 10.1016/j.mce.2005.12.002
  37. 37. New MI, Wilson RC (1999) Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess. Proc Natl Acad Sci U S A 96: 12790–12797. doi: 10.1073/pnas.96.22.12790
  38. 38. Jamieson PM, Chapman KE, Edwards CR, Seckl JR (1995) 11 beta-hydroxysteroid dehydrogenase is an exclusive 11 beta- reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 136: 4754–4761. doi: 10.1210/endo.136.11.7588203
  39. 39. Jamieson PM, Fuchs E, Flugge G, Seckl JR (1997) Attenuation of Hippocampal 11beta-Hydroxysteroid Dehydrogenase Type 1 by Chronic Psychosocial Stress in the Tree Shrew. Stress 2: 123–132. doi: 10.3109/10253899709014743
  40. 40. Grosser BI (1966) 11-beta-Hydroxysteroid metabolism by mouse brain and glioma 261. J Neurochem 13: 475–478. doi: 10.1111/j.1471-4159.1966.tb09861.x
  41. 41. Grosser BI, Axelrod LR (1968) Conversion of cortisol to cortisol acetate, cortisone acetate and cortisone by the developing primate brain. Steroids 11: 827–836. doi: 10.1016/s0039-128x(68)80097-2
  42. 42. Peterson NA, Chaikoff IL, Jones C (1965) The in Vitro Conversion of Cortisol to Cortisone by Subcellular Brain Fractions of Young and Adult Rats. J Neurochem 12: 273–278. doi: 10.1111/j.1471-4159.1965.tb06764.x
  43. 43. Wyrwoll CS, Holmes MC, Seckl JR (2011) 11beta-hydroxysteroid dehydrogenases and the brain: from zero to hero, a decade of progress. Front Neuroendocrinol 32: 265–286. doi: 10.1016/j.yfrne.2010.12.001
  44. 44. Rosmond R, Bjorntorp P (2000) The hypothalamic-pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke. J Intern Med 247: 188–197. doi: 10.1046/j.1365-2796.2000.00603.x
  45. 45. Korz V, Frey JU (2003) Stress-related modulation of hippocampal long-term potentiation in rats: Involvement of adrenal steroid receptors. J Neurosci 23: 7281–7287.
  46. 46. Zipp F, Aktas O (2006) The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci 29: 518–527. doi: 10.1016/j.tins.2006.07.006
  47. 47. Sorrells SF, Sapolsky RM (2007) An inflammatory review of glucocorticoid actions in the CNS. Brain Behav Immun 21: 259–272. doi: 10.1016/j.bbi.2006.11.006
  48. 48. O’Collins VE, Macleod MR, Cox SF, Van Raay L, Aleksoska E, et al.. (2011) Preclinical drug evaluation for combination therapy in acute stroke using systematic review, meta-analysis, and subsequent experimental testing. J Cereb Blood Flow Metab, 31, 962–975.
  49. 49. Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, et al. (2007) Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 69: 1404–1410. doi: 10.1212/01.wnl.0000277487.04281.db